Incidence and risk factors of drug‐induced liver injury

Li, Xiaoyun; Tang, Jieting; Mao, Yimin

doi:10.1111/liv.15262

Cited by 158

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Incidence and risk factors of drug‐induced liver injury

Li, Xiaoyun, Tang, Jieting, Mao, Yimin·2022·Liver International

DOI 10.1111/liv.15262

Open this paper in CoChat — free account

Abstract

The epidemiology and aetiology of drug‐induced liver injury (DILI) vary across different countries and populations. Overall, DILI is rare in the general population but has become more prevalent in hospitalized patients, especially among patients with unexplained liver conditions. In addition, drugs implicated in DILI differ between Western and Eastern countries. Antibiotics are the leading drugs implicated in DILI in the West, whereas traditional Chinese medicine is the primary cause implicated in DILI in the East. The incidence of herbal and dietary supplements‐induced hepatotoxicity is increasing globally. Several genetic and nongenetic risk factors associated with DILI have been described in the literature; however, there are no confirmed risk factors for all‐cause DILI. Some factors may contribute to the risk of DILI in a drug‐specific manner.

Integrity signals

Registry

Crossref · 10.1111/liv.15262

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

HLA polymorphisms associated with certain drugs have also been reported.
“HLA polymorphisms associated with certain drugs have also been reported [1].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [1]
There is insufficient evidence suggesting that currently reported drug- and host-related risk factors can increase all-cause susceptibility to iDILI.
“There is insufficient evidence suggesting that currently reported drug-and host-related risk factors can increase all-cause susceptibility to iDILI [1,27].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [1]
Antineoplastic agents are important causes of drug-induced liver injury.
“Antineoplastic agents are important causes of DILI.”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [1]
Approximately 10% of DILI cases in China and 8.34% in Japan are caused by antineoplastic agents.
“Approximately 10% and 8.34% of DILI cases in China and Japan, respectively, are caused by antineoplastic agents [1].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [1]
In Western countries, antineoplastic agent-induced liver injury accounts for 5-8% of DILI.
“In Western countries, antineoplastic agent-induced liver injury accounts for 5-8% of DILI.”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [1]

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Drug-induced liver injury
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
Self-citation
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
Spigel, D. R., Reynolds, C., Waterhouse, D., Garon, E. B., Chandler, J., Babu, S., Thurmes, P., Spira, A., Jotte, R., Zhu, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.022 · Cited by 229
Ashwagandha‐induced liver injury: A case series from Iceland and the US Drug‐Induced Liver Injury Network
Björnsson, H. K., Björnsson, E. S., Avula, B., Khan, I. A., Jonasson, J. G., Ghabril, M., Hayashi, P. H., & Navarro, V. (2020) · Liver International · doi:10.1111/liv.14393 · Cited by 125
Human leukocyte antigen B∗14:01 and B∗35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury
Li, Y., Phillips, E. J., Dellinger, A., Nicoletti, P., Schutte, R., Li, D., Ostrov, D. A., Fontana, R. J., Watkins, P. B., Stolz, A., et al. (2021) · Hepatology · doi:10.1002/hep.31258 · Cited by 76

Flagged first, then by citations

Research works printed but not linked: 133

10.1038/clpt.2013.16 · DOI
10.1016/j.cld.2019.09.006 · DOI
10.1016/j.cld.2012.03.002 · DOI
10.1038/ajg.2014.131 · DOI · Paper page
10.1053/jhep.2002.34857 · DOI
10.1001/archinte.154.3.311 · DOI
10.1001/archinte.156.12.1327 · DOI
García Rodríguez LA, 1997, A review of epidemiologic research on drug‐induced acute liver injury using the general practice research data base in the United Kingdom, Pharmacotherapy, 17, 721, 10.1002/j.1875-9114.1997.tb03747.x · DOI
10.1111/j.1365-2125.2004.02133.x · DOI
10.1111/j.1365-2036.2006.03117.x · DOI
10.1016/j.gastro.2005.05.006 · DOI
10.1007/s40264-017-0547-9 · DOI
10.1038/ajg.2012.138 · DOI
10.1053/j.gastro.2015.03.006 · DOI · Paper page
10.1053/j.gastro.2008.09.011 · DOI
10.1111/j.1478-3231.2007.01461.x · DOI
10.1002/hep.23577 · DOI · Paper page
10.1002/pds.3603 · DOI
10.1046/j.1365-2125.2000.00282.x · DOI
10.1007/s00228-004-0888-z · DOI
10.1097/MCG.0b013e3181c5e9cc · DOI
10.1016/j.aohep.2018.11.008 · DOI
10.1007/s00204-017-2007-9 · DOI
10.1038/ajg.2010.287 · DOI · Paper page
10.1080/00365520310000492 · DOI
10.1111/j.1572-0241.2006.01019.x · DOI
10.1016/j.cld.2019.09.005 · DOI
10.1111/j.1365-2796.2007.01818.x · DOI
10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
10.1053/j.gastro.2015.02.050 · DOI
10.1111/liv.13535 · DOI
10.1016/j.cgh.2008.09.009 · DOI
10.1002/lt.21119 · DOI
10.1016/j.cgh.2017.07.037 · DOI
10.1016/j.cgh.2017.12.051 · DOI · Paper page
10.1016/j.cgh.2021.01.011 · DOI · Paper page
10.1111/hepr.13288 · DOI · Paper page
10.1111/j.1872-034X.2008.00486.x · DOI · Paper page
10.1038/ajg.2016.114 · DOI
10.14309/ajg.0000000000000201 · DOI · Paper page
10.1002/hep4.1355 · DOI · Paper page
10.1002/hep.31538 · DOI
10.1016/j.yexmp.2014.03.003 · DOI
10.1016/j.phymed.2018.08.011 · DOI
Group CW, 2020, Drug‐induced Liver Injury (DILI): Current Status and Future Directions for Drug Development and the Post‐Market Setting
10.1016/S2213-2600(19)30418-7 · DOI
10.1111/liv.13662 · DOI
10.5604/01.3001.0009.8600 · DOI · Paper page
10.1186/s12943-018-0801-5 · DOI
10.1016/j.ctrv.2012.09.004 · DOI
10.1093/annonc/mdx359 · DOI
10.1038/s41571-020-0413-z · DOI · Paper page
10.1038/nrclinonc.2016.58 · DOI
10.1016/S1470-2045(09)70334-1 · DOI · Paper page
10.1038/s41416-020-01099-7 · DOI
10.1111/liv.13746 · DOI · Paper page
10.1002/hep.22272 · DOI
10.1016/j.jhep.2014.11.019 · DOI
10.1021/jm000407e · DOI
10.1016/j.bmcl.2008.07.071 · DOI
10.1002/hep.26208 · DOI
10.1016/j.jhep.2015.04.016 · DOI
10.1002/hep.28678 · DOI
10.1080/10408440590935620 · DOI
10.1124/dmd.107.019018 · DOI
10.1124/dmd.32.6.639 · DOI
10.3390/ijms17050714 · DOI
10.1053/jhep.2002.30319 · DOI
10.1016/j.jhep.2012.12.018 · DOI
10.1016/j.cbi.2020.109056 · DOI
Massart J, 2017, Role of nonalcoholic fatty liver disease as risk factor for drug‐induced hepatotoxicity, J Clin Transl Res, 3, 212
10.1124/dmd.113.056267 · DOI
10.1046/j.1528-1157.2003.07202.x · DOI
10.1007/s00424-006-0152-8 · DOI
10.1016/j.hepres.2005.12.009 · DOI · Paper page
10.1093/toxsci/kfq269 · DOI · Paper page
10.1016/j.cbi.2010.11.002 · DOI
10.1002/hep.27206 · DOI · Paper page
10.1124/dmd.113.054304 · DOI
10.1016/j.jhep.2010.12.003 · DOI
10.1002/hep4.1346 · DOI · Paper page
10.1016/0895-4356(93)90101-6 · DOI · Paper page
10.1016/j.jhep.2021.01.029 · DOI
10.1016/S2468-1253(20)30006-6 · DOI · Paper page
10.1097/MPG.0b013e31821d6cfd · DOI
10.1038/nrendo.2010.96 · DOI
10.1002/hep.22895 · DOI · Paper page
10.1055/s-0034-1375953 · DOI
10.1111/j.1530-0277.1986.tb05605.x · DOI
10.1002/hep.1840220312 · DOI
10.1016/0002-9343(65)90145-2 · DOI
10.1186/1752-1947-5-461 · DOI
10.1136/bmj.38391.663287.E0 · DOI · Paper page
10.1016/j.jhep.2007.01.024 · DOI · Paper page
10.1053/j.gastro.2019.07.006 · DOI · Paper page
10.1016/j.jhep.2005.11.027 · DOI
10.1097/00002030-199810000-00025 · DOI
10.1097/01.qai.0000243054.58074.59 · DOI
10.1016/j.cgh.2018.12.013 · DOI
10.1517/14740338.6.1.1 · DOI
10.1016/S0002-9343(05)80060-9 · DOI
10.1111/jgh.14889 · DOI
10.1080/17425255.2021.1854726 · DOI · Paper page
10.1016/j.pharmthera.2012.12.007 · DOI · Paper page
10.1111/bcpt.12776 · DOI
10.1053/jhep.2003.50144 · DOI
10.1038/tpj.2011.34 · DOI
10.1002/cpt.924 · DOI
10.1007/s40261-017-0572-6 · DOI
10.3390/ijerph13080776 · DOI
10.5588/ijtld.15.0310 · DOI
10.1016/S1665-2681(19)31302-X · DOI
10.1055/s-0034-1375954 · DOI
10.1007/s00204-020-02885-1 · DOI
10.1053/j.gastro.2019.01.034 · DOI · Paper page
10.1016/0168-8278(90)90124-A · DOI · Paper page
10.2165/00002018-200932010-00005 · DOI · Paper page
10.1002/hep.21095 · DOI
10.1136/gut.47.5.717 · DOI
10.1053/j.gastro.2011.04.001 · DOI
10.1038/ng.379 · DOI
10.1016/j.jhep.2017.03.010 · DOI · Paper page
10.1038/sj.tpj.6500458 · DOI
10.1200/JCO.2013.52.9867 · DOI
10.1200/JCO.2010.31.3197 · DOI
10.1158/1078-0432.CCR-15-2044 · DOI
Li C, 2019, HLA‐B*35:01 allele is a potential biomarker for predicting Polygonum multiflorum‐induced liver injury in humans, Hepatology, 70, 346, 10.1002/hep.30660 · DOI · Paper page
10.1002/cpt.1493 · DOI
10.1056/NEJMoa1013297 · DOI
10.1371/journal.pone.0068111 · DOI
10.1164/rccm.2108091 · DOI
10.1097/FPC.0000000000000209 · DOI
10.1016/j.jhep.2018.08.004 · DOI

Sorted by citations

Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Self-citation
Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury
Xiong, Y.-T., Wang, J.-F., Li, L., Bai, Z.-F., Liu, Y., Huang, A., Wang, K.-X., Fu, Y., Yang, W., Guo, C., et al. (2024) · iLIVER · doi:10.1016/j.iliver.2024.100095 · Cited by 6

Authors: Li, X., Tang, J., & Mao, Y.
Venue: Liver International
Publisher: Wiley
Published: 2022-04-02
Volume: 42
Issue: 9
Pages: 1999-2014
ISSN: 1478-3223
1478-3231
DOI: 10.1111/liv.15262
Cited by: 158
References: 14
Language: en
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Incidence and risk factors of drug‐induced liver injury

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks